Goldman Sachs Annual Global Healthcare Conference w/ Nick Keher

Join our CFO, Nick Keher, at the Goldman Sachs Annual Global Healthcare Conference

BenevolentAI’s Chief Financial Officer will be at the Goldman Sachs Annual Global Healthcare Conference in California on June 13 - June 16, 2022.

Nick Keher


Nick joined Benevolent AI as CFO in March 2022 having previously been CFO of Clinigen, a UK AIM listed Global Pharmaceutical and Pharma Services company with over £450m of revenue. Prior to this Nick was an equity analyst covering the European healthcare space for over eight years, first at Investec and then at RBC where he was Managing Director and Head of RBC’s European healthcare equity research team. Nick began his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (‘GSK’) where he completed his accountancy qualification (ACMA) working within GSK’s finance function.

More Posts

You Might Also Like

BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022